| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Merck has a current Overall Rating of B (Positive). | 7 |
$25 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Cancer Therapies | 23 |
$500 |
| 25-Nov-2009 | New Constructs, LLC |
N/A
| MRK: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 25-Nov-2009 | Pechala's Reports | Lubomir Pechala | MERCK & COMPANY INC (MRK=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 24-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (MRK). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (MRK). | 5 |
$18 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Dow Jones 30 Intelligence Monitor: overall outlook NEUTRAL - 3 new Leaders; 5 new Laggards. | 23 |
$20 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| NYSE US 100 Intelligence Monitor: overall outlook NEUTRAL - 14 new Leaders; 17 new Laggards. | 46 |
$40 |
| 23-Nov-2009 | Reuters Investment Profile |
N/A
| Merck & Co Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Engineering & Research Industry Trends, Statistics & Analysis 2009 (Summary) | 70 |
$199 |
0.16% Nasdaq 0.00%
Research Reports
